MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qai.0000000000003506

Медицинская библиотека · Journal of acquired immune deficiency syndromes (1999) · 2024

Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037).

Ho Ken, Hoesley Craig, Anderson Peter L, Fernández-Romero Jose A, Friedland Barbara A, Kelly Clifton W, Jiao Yuqing, Edick Stacey, Brand Rhonda, Kunjara Na Ayudhya Ratiya Pamela, Zyhowski Ashley, Hartman Douglas J, Reddy Nipun B, Al-Khouja Amer, Piper Jeanna, Bauermeister Jose A, Teleshova Natalia, Melo Claudia, Cornejal Nadjet, Barnable Patrick, Singh Devika, Scheckter Rachel, McClure Tara, Hillier Sharon L, Hendrix Craig W, MTN-037 Study Team

СтатьяКлиническое исследование I фазыПеревод пока не подготовлен

Аннотация

BACKGROUND

On demand, topical PrEP is desired by those preferring episodic, nonsystemic PrEP. PC-1005 gel (MIV-150, zinc, and carrageenan) exhibits in vitro antiviral HIV-1, human papillomavirus (HPV), and herpes simplex virus type 2 (HSV-2) activity, attractive for a multipurpose prevention technology candidate. We evaluated the safety, pharmacokinetics, and antiviral effect of rectally applied PC-1005.

METHODS

HIV-uninfected adults received a series of 3 rectal PC-1005 doses-4, 16, and 32 mL separated by 2-week washout periods. Following each dose, plasma, rectal fluid and tissue, and vaginal fluid were collected over 48 hours.

RESULTS

Thirteen adults enrolled; 12 completed all 3 doses. All 13 adverse events reported were grade 1 or 2; 5 were judged study drug related. Plasma MIV-150 peaked 1-2 h after dosing with a median peak concentrations range of 0.07-0.23 ng/mL and median half-life range of 4.9-7.4 hours across dose volumes; median concentrations were below assay quantitation limits (BLQ) 24 hours after dosing. Rectal tissue MIV-150 peaked 0.5-1 hours after dosing at 1.4 ng/g (ng/mL) (0.8, 1.9), 46.0 (30.7, 831.0), and 79.7 (11.9, 116.0), respectively, after each dose volume; median tissue concentrations were BLQ beyond 5 hours for all doses. All vaginal fluid samples were BLQ. Ex vivo antiviral assays showed 5 hours of antiviral HPV and HSV effects but no anti-HIV activity.

CONCLUSIONS

MIV-150 rectal tissue concentrations were below the 100 ng/g target concentration and transient. Ex vivo assays demonstrated antiviral HSV and HPV effects but not against HIV. PC-1005 requires a more potent antiviral and longer-lasting formulation for further consideration as a multipurpose prevention technology candidate.

CLINICAL TRIALS: NCT03408899.

Для цитирования: Ho Ken, Hoesley Craig, Anderson Peter L, Fernández-Romero Jose A, Friedland Barbara A, Kelly Clifton W, Jiao Yuqing, Edick Stacey, Brand Rhonda, Kunjara Na Ayudhya Ratiya Pamela, Zyhowski Ashley, Hartman Douglas J, Reddy Nipun B, Al-Khouja Amer, Piper Jeanna, Bauermeister Jose A, Teleshova Natalia, Melo Claudia, Cornejal Nadjet, Barnable Patrick, Singh Devika, Scheckter Rachel, McClure Tara, Hillier Sharon L, Hendrix Craig W, MTN-037 Study Team. Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037).. Journal of acquired immune deficiency syndromes (1999). 2024. DOI: 10.1097/qai.0000000000003506.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.